The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

CRISPR’s lengthy patent legal battle could finally end—in a tie

| | March 11, 2019

Like a couple of heavyweight boxers who just keep slugging it out, the University of California Berkeley (UCB) and the Broad Institute continue to pummel each other through the courts. No knockout blows yet, but in the latest ruling from the US Patent and Trademark Office, UCB may finally be ahead on points.

These two behemoths of genetic research are fighting over ownership of the breakthrough technology known as CRISPR-Cas9.

In the USA the valuable claims were granted for the Broad Institute. UCB cried foul, insisting that Feng Zhang’s demonstration that he could make gene-editing work in cells was nothing more than an obvious add-on to the work of Doudna and Charpentier and shouldn’t be given a dominant patent position.

Related article:  BRCA mutations can be deadly or harmless. Now CRISPR can tell the difference

The US Patent and Trademark Office has now completed its examination of a key patent application from UCB, and has signalled that it intends to accept their claims.

A tie is very rare in a boxing match. But perhaps in this contest we’re approaching the time for the two corners to get together and agree cross-licensing strategies and agreements before everyone is too punch-drunk to continue fighting effectively.

Read full, original post: The epic legal battle over CRISPR’s future could finally be over

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend